NEW POSSIBILITIES OF THERAPY OF INTENSIVELY PRETREATED METASTATIC COLORECTAL CANCER PATIENTS

Abstract

The review deals with research of new multikinase inhibitor regorafenib used for treatment of chemorefractory metastatic colorectal cancer. Regorafenib inhibits various protein kinases implicated in oncogenesis, angiogenesis, and the tumour microenvironment. In two placebo- controlled, randomized, phase III trials (CORRECT and CONCUR) treatment with regorafenib has demonstrated statistically significant improvements in terms of overall survival, progression-free urvival and disease control rates when compared with placebo in pretreated patients. Correlative analyses suggest a clinical benefit favouring regorafenib across various patient subgroups including subgroups defined by KRAS mutational status and other biomarkers. The most common grade ≥3 adverse events were hand-foot syndrome, fatigue, diarrhea, hypertension and rash/desquamation. The benefit provided by regorafenib was observed in two open-label, single-arm studies (REBECCA and CONSIGN) performed in the real-world setting.